Claims for Patent: 8,642,068

Summary for Patent: 8,642,068

Title:	Bioabsorbable medical device with coating
Abstract:	A biodegradable, bioabsorbable medical device with a coating for capturing progenitor endothelial cells in vivo and delivering a therapeutic agent at the site of implantation. The coating on the medical device is provided with a biabsorbable polymer composition such as a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive for controlling the rate of delivery of the therapeutic agent.
Inventor(s):	Cottone; Robert J. (Davie, FL)
Assignee:	Orbusneich Medical, Inc. (Ft. Lauderdale, FL)
Application Number:	13/098,850
Patent Claims:	1. An expandable stent, comprising crystallized bioabsorbable material and a coating, wherein the expandable stent comprises a plurality of first meandering strut patterns, each first meandering strut pattern being interconnected to one another to form an interconnected mesh and at least two second strut patterns nested within the interconnected mesh, each second strut pattern comprising a hoop circumferential about the longitudinal axis of the expandable stent, wherein the second strut patterns crystallize when the stent is expanded, and wherein the coating comprising a bioabsorbable matrix and a ligand. 2. The expandable stent of claim 1, wherein each second strut pattern further comprises at least one hoop having a through-void, wherein the hoop is configured to permit its radius to be expanded when subject to an expanding force which exceeds its nominal expanded state. 3. The expandable stent of claim 1 wherein the bioabsorbable material comprises at least about 70% by weight of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co PEG moiety, linked with a modifying copolymer comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-.epsilon.-caprolactone) or poly (D-lactide-co-.epsilon.-caprolactone) in the form of block copolymers or blocky random copolymers. 4. The expandable stent of claim 1, wherein the ligand is configured to bind target cells in vivo. 5. The expandable stent of claim 4, wherein the ligand is a small molecule, a peptide, an antibody, antibody fragments, or combinations thereof and the target cell is a progenitor endothelial cell antigen. 6. The expandable stent of claim 1, wherein the bioabsorbable matrix comprises a naturally occurring or synthetic biodegradable polymer. 7. The expandable stent of claim 1, wherein the bioabsorbable matrix comprises at least one of the group consisting of: dextran, tropoelastin, elastin, laminin, fibronectin, fibrin, collagen, basement membrane proteins, and cross-linked tropoelastin. 8. The expandable stent of claim 1 impregnated with a pharmacological substance. 9. The expandable stent of claim 8, wherein the pharmacological substance is at least one of the group consisting of: cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, biolimus A9, CCI-779, RAD 001, AP23573, azathioprene, pimecrolimus, tacrolimus (FK506), tranilast, dexamethasone, corticosteroid, everolimus, retinoic acid, vitamin E, rosglitazone, simvastatins, fluvastatin, estrogen, 17.beta.-estradiol, hydrocortisone, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumab, sulindac, dihydroepiandrosterone, testosterone, puerarin, platelet factor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives, LBM-642, deforolimus, and probucol.

Details for Patent 8,642,068

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2026-10-20